本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Revolution Medicines, Inc.

203.77
+0.42000.21%
盤後203.770.00000.00%19:51 EDT
成交量:137.87萬
成交額:2.79億
市值:436.75億
市盈率:-22.84
高:206.36
開:204.98
低:197.81
收:203.35
52周最高:224.31
52周最低:42.18
股本:2.14億
流通股本:1.85億
量比:1.07
換手率:0.75%
股息:- -
股息率:- -
每股收益(TTM):-8.9212
每股收益(LYR):-5.9502
淨資產收益率:-79.09%
總資產收益率:-30.12%
市淨率:16.76
市盈率(LYR):-34.25

資料載入中...

2021/03/02

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2021/03/02

重要事件披露

8-K - Current report
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/11

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/10

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/08

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/03

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/02/02

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/01

SEC問詢函

CORRESP [Cover] - Correspondence
2021/02/01

SEC問詢函

CORRESP [Cover] - Correspondence
2021/02/01

招股説明書

S-1 - General form for registration of securities under the Securities Act of 1933
2021/02/01

重要事件披露

8-K - Current report
2020/11/12

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2020/11/12

重要事件披露

8-K - Current report
2020/08/10

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2020/08/10

重要事件披露

8-K - Current report
2020/07/06

SEC問詢函

CORRESP [Cover] - Correspondence